Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
Tue, 11/27/18 - 11:57 am
Alzheimer's disease
NASH
RNA
gene therapy
immuno-oncology
orphan diseases
Genfit plans US listing as NASH drugmakers race to the finish line
Endpoints
Mon, 11/19/18 - 11:44 pm
Genfit
IPOs
NASH
CymaBay Therapeutics Reports Positive Results from Ph II Study of Seladelpar in Patients with Primary Biliary Cholangitis
CP Wire
Tue, 11/13/18 - 10:26 am
CymaBay
seladelpar
primary biliary cholangitis
NASH
CymaBay Therapeutics Reports Positive Results from Ph II Study of Seladelpar in Patients with Primary Biliary Cholangitis
Tue, 11/13/18 - 10:02 am
CymaBay
seladelpar
primary biliary cholangitis
NASH
NASH drugs come into focus as field awaits late-stage data
BioSpace
Sat, 11/10/18 - 12:43 pm
NASH
Intercept Pharma
Gilead Sciences
Genfit
Allergan
NASH Treatment: Will a Combo Drug Developed by Novartis and Pfizer Make the Cut?
Xtalks
Thu, 11/1/18 - 07:13 pm
Pfizer
Novartis
NASH
Big Pharma rivals Pfizer and Novartis team up on NASH combo targets
Fierce Biotech
Mon, 10/29/18 - 11:50 am
Pfizer
Novartis
NASH
drug development
Innovate Biopharmaceuticals Announces Promising Results of Larazotide in NASH Study
CP Wire
Mon, 10/29/18 - 09:57 am
Innovate Biopharmaceuticals
larazotide acetate
NASH
celiac disease
Innovate Biopharmaceuticals Announces Promising Results of Larazotide in NASH Study
Mon, 10/29/18 - 09:56 am
Innovate Biopharmaceuticals
larazotide acetate
NASH
celiac disease
89Bio Joins NASH Chase with a Teva Drug and $60M in Funding
Xconomy
Thu, 10/25/18 - 11:19 pm
89Bio
Teva Pharmaceutical
NASH
ENDRA Life Sciences Receives Canadian Approval for Human Studies of its Taeus Device to Detect Non-Alcoholic Fatty Liver Disease
CP Wire
Tue, 10/16/18 - 09:39 am
ENDRA Life Sciences
TAEUS
devices
NASH
Eyeing NASH, Glympse Raises $22M to Test Disease Detection Nanotech
Xconomy
Tue, 10/9/18 - 11:30 pm
Glympse Bio
diagnostics
NASH
nanotech
Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD
BioCentury
Tue, 10/2/18 - 11:01 pm
Gilead Sciences
NASH
GS-9674
FXR agonists
Promising study results thrust Viking Therapeutics into race for lucrative fatty liver disease treatment
Stat
Tue, 09/18/18 - 10:00 am
Viking Therapeutics
NASH
non-alcoholic fatty liver disease
VK2809
clinical trials
UCSD researchers identify mechanism, target in NASH
BioCentury
Sat, 09/15/18 - 02:12 pm
NASH
Novartis
What's Next for Gilead Sciences After Its Latest Clinical Success
Motley Fool
Thu, 09/13/18 - 12:00 pm
Gilead Sciences
John Milligan
HIV
NASH
filgotinib
Gemphire's lead drug worsened disease, investigators conclude in ending trial
Biopharma Dive
Fri, 08/10/18 - 02:09 pm
Gemphire Therapeutics
clinical trials
NASH
3 Biotech Stocks With Big News Coming in NASH
Motley Fool
Sat, 07/14/18 - 01:11 pm
NASH
Viking Therapeutics
Gilead Sciences
Intercept Pharma
VK2809
Ocalivia
selonsertib
Akero picks up $65M to advance Amgen-licensed NASH drug
Fierce Biotech
Mon, 06/25/18 - 09:28 am
Akeron Therapeutics
NASH
Amgen
AKR-001
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
Motley Fool
Fri, 06/15/18 - 07:04 pm
NASH
liver disease
Viking Therapeutics
Madrigal Pharmaceuticals
Pfizer
Bristol-Myers Squibb
Gilead Sciences
Pages
« first
‹ previous
…
7
8
9
10
11
12
13
14
15
next ›
last »